GLP-1 drugs like semaglutide and liraglutide are revolutionizing diabetes and obesity care by enhancing glucose control and driving weight loss. Their complex manufacturing spanning peptide synthesis, formulation, sterile injectables, and cold-chain logistics poses challenges but also opportunities. With global demand soaring and annual sales projected to exceed $100 billion by 2030, supply chain bottlenecks and device shortages remain critical barriers. As patents for blockb

This blog explores how the fixed-dose combination of Pantoprazole 40 mg + Domperidone 10 mg delivers a dual-action advantage in GERD and acid-related disorders. By combining Pantoprazole’s powerful acid suppression with Domperidone’s prokinetic action, it ensures faster relief, improved gastric motility, and long-lasting patient comfort. The article highlights its clinical superiority over monotherapy, regulatory acceptance, and formulation excellence by Walter Healthcare, ma

Pharmaceutical packaging: not just a container, but a vital protector. It's the silent guardian ensuring your medicine remains safe,...

The India-UK Free Trade Agreement unlocks zero-duty access and faster approvals for Indian pharma exports, paving the way for deeper...